Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. Its clinical stage products include ruxolitinib cream, which is in Phase II clinical trial for the treatment of alopecia areata; and INCB52793, which is in Phase I/II for the treatment of advanced malignancies. The company’s clinical stage products also comprise baricitinib, which is in Phase III trial for rheumatoid arthritis, as well as completed Phase II trial for psoriasis and diabetic nephropathy; and in Phase II trial for atopic dermatitis. In addition, it is developing INCB39110, which is in Phase I/II trial in combination with osimertinib for lung cancer, as well as in Phase I/II trial in combination with pembrolizumab for advanced malignancies; and in Phase II trial for graft versus host disease. Further, the company’s clinical stage products include epacadostat, which is in Phase II trial for various tumors, and in Phase I/II trial for non-small cell lung cancer, as well as for advanced melanoma. Additionally, it is developing INCB54329 (BRD) and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB50465 (PI3Kd), which is in Phase I/II trial for B-cell malignancies and solid tumors; INCB54828 (FGFR) and INCSHR1210, which are in I/II trials for solid tumors; and capmatinib, which is in Phase II clinical trial for the treatment of non-small cell lung, glioblastoma, and liver cancer. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It operates in the United States and internationally. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Pfizer Inc.; and Jiangsu Hengrui Medicine Co., Ltd. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.